
## Daniel D Murray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1677842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	13.9	357
2	Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression. Journal of Immunology, 2012, 188, 6238-6246.	0.4	152
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	2.0	56
4	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	6.3	48
5	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biology, 2011, 8, 1035-1046.	1.5	45
6	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981.	1.1	45
7	Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. Blood Advances, 2020, 4, 5797-5809.	2.5	42
8	mi <scp>RNA</scp> s and <scp>HIV</scp> : unforeseen determinants of hostâ€pathogen interaction. Immunological Reviews, 2013, 254, 265-280.	2.8	37
9	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Scientific Reports, 2017, 7, 10934.	1.6	36
10	The role of microRNAs in HIV-1 pathogenesis and therapy. Aids, 2012, 26, 1325-1334.	1.0	34
11	Sepsis: Personalized Medicine Utilizing â€~Omic' Technologies—A Paradigm Shift?. Healthcare (Switzerland), 2018, 6, 111.	1.0	20
12	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy–Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. Journal of Infectious Diseases, 2019, 220, 1325-1334.	1.9	18
13	Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz086.	0.4	17
14	Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance. Journal of Clinical Medicine, 2019, 8, 1163.	1.0	16
15	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). Clinical Trials, 2022, 19, 52-61.	0.7	16
16	The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. Aging, 2021, 13, 22732-22751.	1.4	14
17	Integrative Lipidomics and Metabolomics for System-Level Understanding of the Metabolic Syndrome in Long-Term Treated HIV-Infected Individuals. Frontiers in Immunology, 2021, 12, 742736.	2.2	11
18	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. American Journal of Hypertension, 2020, 33, 43-52.	1.0	6

DANIEL D MURRAY

#	Article	IF	CITATIONS
19	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. Journal of Infectious Diseases, 2021, 224, 2053-2063.	1.9	6
20	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 1141-1146.	2.9	2
21	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. Aids, 2021, 35, 783-789.	1.0	2
22	2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. Open Forum Infectious Diseases, 2019, 6, S892-S893.	0.4	0